Search results
Added:
6 months ago
Source:
Radcliffe Vascular
Thoracic aortic aneurysms and dissections (TAADs) are life-threatening conditions with limited pharmacological options, often necessitating high-risk surgical repair.² A key pathological feature is aortic medial degeneration, marked by the accumulation of a glycan-rich matrix. A new study published in the European Heart Journal has identified a metabolic pathway that drives this process,…
View more
Added:
7 months ago
Source:
Radcliffe Cardiology
Hyperlipidaemia and inflammation are known contributors to cardiovascular risk, but their combined impact, particularly in patients on treatment, requires further clarification. A new longitudinal analysis of UK Biobank data has found that low-density lipoprotein cholesterol (LDL-C), lipoprotein(a) [Lp(a)], and high-sensitivity C-reactive protein (Hs-CRP) are independent and synergistic…
View more
Added:
11 months ago
Source:
Radcliffe CVRM
The assessment of lipid-related cardiovascular risk has traditionally focused on low-density lipoprotein cholesterol (LDL-C), but debate continues over the relative atherogenicity of different apolipoprotein B-containing lipoprotein particles (apoB-P). A large prospective analysis published in the European Heart Journal provides clarity, suggesting that the total count of apoB-P and lipoprotein(a…
View more
Added:
4 months ago
Source:
Radcliffe CVRM
The human metabolome reflects a complex interplay of genetic and environmental factors. A large-scale analysis integrating blood metabolomic, genomic, and lifestyle data from ten prospective cohorts has identified a comprehensive profile of circulating metabolites that are associated with the future risk of developing type 2 diabetes (T2D).¹MethodologyResearchers conducted a pooled analysis of 23…
View more
Added:
1 year ago
Source:
Radcliffe CVRM
AUTHOR: Ola WisniewskaSodium-glucose cotransporter-2 (SGLT2) inhibitors significantly slow kidney function decline in patients with type 2 diabetes, with even greater benefits seen in those with higher body mass index (BMI), according to a nationwide Japanese study published recently.1Researchers analyzed data from 2,165 patients prescribed SGLT2 inhibitors compared with 4,330 matched patients on…
View more
Added:
3 months ago
Source:
Radcliffe CVRM
For patients with elevated lipoprotein(a) [Lp(a)] and established cardiovascular disease (CVD), weekly lipoprotein apheresis (LA) is the only approved treatment, but it represents a significant burden. The Lp(a)FRONTIERS APHERESIS trial investigated whether the investigational therapy pelacarsen could reduce the need for this invasive procedure.¹Mechanism of ActionPelacarsen is a hepatocyte…
View more
Added:
5 months ago
Source:
Radcliffe CVRM
A new study has defined a metabolome-informed body mass index (metBMI) that more accurately reflects adiposity and cardiometabolic risk than the traditional BMI calculation.² The findings, published in Nature Medicine, suggest this multi-omic approach could help identify high-risk individuals whose metabolic dysfunction is not captured by conventional measures.¹MethodologyResearchers developed…
View more
Added:
6 months ago
Source:
Radcliffe CVRM
Elevated lipoprotein(a) [Lp(a)] is a known causal risk factor for atherosclerotic cardiovascular disease (ASCVD), with vascular inflammation considered a key mechanism.² A new analysis has investigated whether interleukin-6 (IL-6), a biomarker of inflammation, can help to further stratify cardiovascular risk in individuals with elevated Lp(a). The study analysed data from two large, independent…
View more
Added:
9 months ago
Source:
Transcatheter Academy
The use of paclitaxel-coated devices did not reduce the rate of major amputations or death in patients with chronic limb-threatening ischaemia (CLTI) undergoing infrainguinal endovascular revascularisation, according to the results of a large registry-based trial.¹ While drug-coated devices are commonly used in peripheral interventions, their effect on amputation risk has been uncertain.²The…
View more
Added:
10 months ago
Source:
Radcliffe CVRM
Traditional methods for diagnosing and monitoring type 2 diabetes (T2D), such as episodic glycated haemoglobin (HbA1c) assays, may not fully capture the complex, multifaceted nature of the disease. A new study suggests that a multimodal artificial intelligence (AI) approach, integrating data from wearables, genomics, and the gut microbiome, can provide a more detailed and informative phenotype…
View more